US FDA approves Myrbetriq (extended-release mirabegron) for treatment of neurogenic detrusor overactivity in children ≥3 years

Efficacy of Myrbetriq and Myrbetriq Granules for this indication was established in a study of 86 patients aged 3-17, in which treatment was associated improvements in a number of endpoints, including maximum cystometric capacity and number of daily urine leakage episodes.

Source:

US Food and Drug Administration